StockData
Fate Therapeutics Inc logo

Fate Therapeutics Inc (FATE) stock

FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3024% below fair value
$1.02−0.12 (-10.53%)

Close on Nov 17, 2026Market cap $122.22MP/E –Yield –

Fate Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Fate Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $6.49M, down 23.4% year over year. For fiscal 2025 it was $6.65M, down 51.2% from the year before. Over ten years it grew 10.6% a year on average. The highest annual figure on record is $96.30M in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.65M-51.2%
FY2024Dec 31, 2024$13.63M-78.5%
FY2023Dec 31, 2023$63.53M-34.0%
FY2022Dec 31, 2022$96.30M+72.4%
FY2021Dec 31, 2021$55.85M+77.7%
FY2020Dec 31, 2020$31.43M+194.3%
FY2019Dec 31, 2019$10.68M+125.3%
FY2018Dec 31, 2018$4.74M+15.4%
FY2017Dec 31, 2017$4.11M-6.7%
FY2016Dec 31, 2016$4.40M+81.1%
FY2015Dec 31, 2015$2.43M+150.4%
FY2013Dec 31, 2013$971.00K-63.6%
FY2012Dec 31, 2012$2.67M+128.2%
FY2011Dec 31, 2011$1.17M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.08M+9.2%
Q1 FY2026Mar 31, 2026$1.30M-20.3%
Q4 FY2025Dec 31, 2025$1.37M-26.4%
Q3 FY2025Sep 30, 2025$1.74M-43.4%
Q2 FY2025Jun 30, 2025$1.91M-71.8%
Q1 FY2025Mar 31, 2025$1.63M-15.4%
Q4 FY2024Dec 31, 2024$1.86M+11.0%
Q3 FY2024Sep 30, 2024$3.07M+58.1%
Q2 FY2024Jun 30, 2024$6.77M+625.8%
Q1 FY2024Mar 31, 2024$1.93M-96.7%
Q4 FY2023Dec 31, 2023$1.68M-96.2%
Q3 FY2023Sep 30, 2023$1.94M-87.0%
Q2 FY2023Jun 30, 2023$933.00K-95.0%
Q1 FY2023Mar 31, 2023$58.98M+220.3%
Q4 FY2022Dec 31, 2022$44.36M+159.9%
Q3 FY2022Sep 30, 2022$14.98M+5.3%
Q2 FY2022Jun 30, 2022$18.55M+38.3%
Q1 FY2022Mar 31, 2022$18.41M+65.3%
Q4 FY2021Dec 31, 2021$17.07M+7.4%
Q3 FY2021Sep 30, 2021$14.23M+88.2%
Q2 FY2021Jun 30, 2021$13.41M+145.4%
Q1 FY2021Mar 31, 2021$11.14M+343.0%
Q4 FY2020Dec 31, 2020$15.90M+467.3%
Q3 FY2020Sep 30, 2020$7.56M+211.2%
Q2 FY2020Jun 30, 2020$5.47M+94.0%
Q1 FY2020Mar 31, 2020$2.52M-4.4%
Q4 FY2019Dec 31, 2019$2.80M+68.7%
Q3 FY2019Sep 30, 2019$2.43M+136.7%
Q2 FY2019Jun 30, 2019$2.82M+174.3%
Q1 FY2019Mar 31, 2019$2.63M+156.5%
Q4 FY2018Dec 31, 2018$1.66M+61.7%
Q3 FY2018Sep 30, 2018$1.03M0.0%
Q2 FY2018Jun 30, 2018$1.03M+0.1%
Q1 FY2018Mar 31, 2018$1.03M-0.1%
Q4 FY2017Dec 31, 2017$1.03M0.0%
Q3 FY2017Sep 30, 2017$1.03M0.0%
Q2 FY2017Jun 30, 2017$1.03M–
Q1 FY2017Mar 31, 2017$1.03M–
Q4 FY2016Dec 31, 2016$1.03M–
Q3 FY2016Sep 30, 2016$1.03M–

More Fate Therapeutics figures

See a number that looks wrong?